Imagine the unimaginable: losing your child in the blink of an eye to a disease you thought they were protected against. This is the heartbreaking reality driving a desperate plea for wider access to the meningococcal B vaccine in Victoria, Australia.
Victorian GPs are joining forces with a grieving mother to urge the state government to fully fund meningococcal B vaccinations for young people. Their call to action comes after the tragic and sudden death of 16-year-old Levi Syer-Peterson, who succumbed to the B strain of the disease just a month after being vaccinated against the other four common strains (A, C, Y, and W).
Norliah Syer-Peterson, Levi's mother, voiced her anguish on A Current Affair, highlighting the lack of awareness surrounding the meningococcal B vaccine. "When you go to the doctors, there's no poster saying have you been vaccinated for meningococcal B, there's no awareness out there," she lamented. This lack of readily available information leaves many parents unaware of the potential risk and the preventative measures they could take.
It's crucial to understand that meningococcal disease, a severe bacterial infection, poses the greatest threat to babies and teenagers. The infection spreads through close contact via respiratory droplets – think coughing, sneezing, or even sharing drinks. The initial symptoms can easily be mistaken for common illnesses. "It just sounds like a normal bug or virus, that's how it presented," Syer-Peterson explained, underscoring the deceptive nature of the disease.
Currently, only South Australia, the Northern Territory, and Queensland offer free meningococcal B vaccines to their at-risk residents. In Victoria, however, parents face a significant financial burden, with the vaccine costing between $400 and $600 for the recommended two to three doses.
Syer-Peterson tearfully expressed that she would have willingly paid for the vaccine had she known her son wasn't protected. "We're in a position where we could have afforded to pay for it if we had known about it," she stated, a sentiment that resonates with many families who prioritize their children's health.
Levi's death occurred less than 24 hours after the onset of symptoms, a chilling reminder of the disease's rapid progression. "We had a boy that came home with a stiff neck and a tummy ache… to then have him wake up at 1.30am fighting for his life, and by 7.40am he was gone," Syer-Peterson recounted, her words painting a vivid picture of the family's devastating loss. "I can't describe to you what it's like watching your son die in front of you."
The statistics are grim: one in ten people who contract meningococcal B will die. So far this year, Australia has recorded 72 cases, with 14 occurring in Victoria.
Dr. Anita Munoz, Victoria chair of the Royal Australian College of General Practitioners (RACGP), is a strong advocate for change. "RACGP is calling for the Victorian government to fund the meningitis B vaccine and to protect all Victorian children from this deadly disease," she declared.
But here's where it gets controversial... Dr. Munoz raises a critical point about preventative healthcare. "One of the issues here that is of concern to me, is waiting for us to report a certain number of deaths before we're prepared to intervene and start an immunisation programme," she stated. "That's a difficult thing for the Victorian and Australian public to accept, that we're willing to allow more young people to die, before we decide that it makes economic sense to roll out a vaccine program." This raises the ethical question of how much weight should be given to economic factors when dealing with potentially life-saving preventative measures, especially when children's lives are at stake.
Fueled by grief and a determination to prevent similar tragedies, Syer-Peterson has launched a petition and vowed to continue her fight until Victoria aligns with other states in protecting its youth. "I want everyone in Australia to know that meningococcal B is a real disease. It can happen to anyone," she emphasized. And this is the part most people miss: it's not just about protecting your own children; it's about creating a safer community for everyone. "If something's preventable, what are you waiting for?" she powerfully asks.
In response to the growing pressure, the Department of Health, Disability and Ageing issued a statement. According to the statement, The Victorian Minister for Health has recently addressed the issue with the relevant minister.
The statement clarified that the Meningococcal B vaccine is currently available through the National Immunisation Program (NIP) for Aboriginal and Torres Strait Islander children under 2 years of age, and people older than 2 months with specific medical conditions that heighten their risk.
The Department further explained the process for vaccine inclusion in the NIP. Under the National Health Act 1953, a vaccine can only be added to the NIP (making it free) after a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC evaluates a vaccine's clinical effectiveness, safety, and cost-effectiveness compared to other treatments.
And this is the part most people miss... While the government is responsible for listing vaccines, it is the pharmaceutical companies that apply to the PBAC for consideration.
The pharmaceutical company responsible for Bexsero®, GlaxoSmithKline (GSK), has submitted four applications to the PBAC, the last one being in 2019. This application had a positive recommendation for Aboriginal and Torres Strait Islander infants up to 2 years of age and people with specific medical conditions. Since 2019, GSK has not submitted any further applications.
The Department of Health, Disability and Ageing stated that they are in communication with GSK and welcome an updated submission to the PBAC to reconsider expanding Bexsero's availability.
However, pharmaceutical companies are private entities and cannot be forced to apply to the PBAC. Each company makes its own decisions about the availability and pricing of its medicines and whether to apply for NIP listing.
It's important to note that some Australian states and territories, like Queensland, Northern Territory, and South Australia, have independently funded meningococcal B vaccination programs. This demonstrates that states can choose to provide access to vaccines regardless of the PBAC and NIP.
The Department of Health, Disability and Ageing reiterated its willingness to engage with GSK and encourages an updated submission to the PBAC.
This situation begs the question: Should access to potentially life-saving vaccines be solely dependent on a pharmaceutical company's decision to apply for government funding? Is it ethical to allow cost considerations to outweigh the potential to prevent serious illness and death, especially in vulnerable populations? What is the right balance between individual responsibility and government obligation when it comes to preventative healthcare? Share your thoughts and opinions in the comments below.
